. . "DAPSONE"@en . . "approved"@en . "Bis(P-aminophenyl) sulfone"@en . "4-(4-amino-Benzenesulfonyl)-phenylamine"@en . "P-Aminophenyl sulfone"@en . "4-(4-Aminophenylsulfonyl)benzenamine"@en . . "4,4'-Diaminodiphenylsulfone"@en . "Dapsonum"@en . "Bis(4-aminophenyl)sulfone"@en . "80-08-0"@en . "P,P-Sulphonylbisbenzamine"@en . . "Bioavailability is 70 to 80% following oral administration."@en . "Mycobacterium leprae"@en . "4,4'-Sulfonylbisaniline"@en . "DIAPHENYLSULFONE"@en . . . . . . . . "28 hours (range 10-50 hours)"@en . . . . . . . . . . . "DADPS"@en . " "@en . . . . "DDS"@en . . "Take without regard to meals."@en . "Overdosage might be expected to produce nasal congestion, syncope, or hallucinations. Measures to support blood pressure should be taken if necessary."@en . . . . . . . . "4,4'-Dapsone"@en . . "Weijiard, J.and Messerly, J.P.; U.S. Patent 2,385,899; October 2,1945; assigned to Merck & Co., Inc."@en . . "4,4'-sulfonyldianiline"@en . . . . . "P,P-Sulphonylbisbenzenamine"@en . . . . "Dapsona"@en . . . . . . . . . . . . "4-Aminophenyl sulfone"@en . "1,1'-Sulfonylbis[4-aminobenzene]"@en . . . . . "4,4'-Sulfonylbisbenzenamine"@en . . . . . "investigational"@en . . . "1,1'-Sulfonylbis(4-aminobenzene)"@en . . "4-(4-Aminophenylsulfonyl)aniline"@en . . . . "A sulfone active against a wide range of bacteria but mainly employed for its actions against mycobacterium leprae. Its mechanism of action is probably similar to that of the sulfonamides which involves inhibition of folic acid synthesis in susceptible organisms. It is also used with pyrimethamine in the treatment of malaria. (From Martindale, The Extra Pharmacopoeia, 30th ed, p157-8)"@en . "4,4'-Diaminodiphenyl sulphone"@en . . "P,P'-diaminodiphenyl sulfone"@en . "70 to 90%"@en . . "Dapsone"@en . . "4,4'-Diaminodiphenyl sulfone"@en . "Renal"@en . . . "For the treatment and management of leprosy and dermatitis herpetiformis."@en . "4,4'-Sulfonyldianilin"@en . . . "Dapsone acts against bacteria and protozoa in the same way as sulphonamides, that is by inhibiting the synthesis of dihydrofolic acid through competition with para-amino-benzoate for the active site of dihydropteroate synthetase. The anti-inflammatory action of the drug is unrelated to its antibacterial action and is still not fully understood."@en . "Mycobacteria"@en . "4,4'-Sulfonylbisbenzeneamine"@en .